Reach Us +1-947-333-4405


Michael Retsky | OMICS International
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1174

Journal of Clinical & Experimental Pathology received 1174 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Michael Retsky

Harvard School of Public Health, Boston. MA 02115, USA


Michael Retsky is currently working as a Professor at Harvard School of Public Health, Boston. MA 02115, USA. The author's research interests include Clinical Pathology, Histopathology, Hemato Pathology, Surgical Pathology, Diagnosis. The author is serving as an editorial member and reviewer of several international reputed journals. The author has successfully completed his administrative responsibilities. The author has authorized many research articles/books related to Clinical Pathology, Experimental Pathology.


How long should Adjuvant Chemotherapy be given in Early Stage Colon Cancer?

After diagnosis of colon cancer, the tumor is removed and the stage of the disease is provided by a pathologist. If the stage indicates relatively high risk of relapse, adjuvant chemotherapy is used for 6 or so months to reduce the probability of such relapse. This is a very common situation in oncology – used for many early stage colon can... Read More»

Michael Retsky

Letter to Editor: J Clin Exp Pathol 2013, 3: 136

DOI: 10.4172/2161-0681.1000136

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article